Akso Health (AHG) Research & Development (2016 - 2019)

Akso Health (AHG) has reported Research & Development for 4 consecutive years, with $9.3 million the latest figure, recorded in Q3 2019.

• For the quarter ending Q3 2019, Research & Development fell 21.14% year-over-year to $9.3 million; the trailing twelve-month figure through Sep 2019 stood at $25.7 million (down 20.68% YoY), and the FY2024 full-year result was $168421.0, up 2428.46% from the prior year.
• Research & Development advanced to $9.3 million in Q3 2019 per AHG's latest filing, from $7.5 million in the prior quarter.
• Across five years, Research & Development topped out at $11.7 million in Q3 2018 and bottomed at $831854.0 in Q3 2016.
• Historically, Research & Development has averaged $5.3 million across 4 years, with a median of $3.7 million in 2017.
• The sharpest annual moves came in 2018 and 2019: Research & Development jumped 354.15% in 2018, then sank 50.48% in 2019.
• Over 4 years, Research & Development stood at $1.4 million in 2016, then soared by 288.33% to $5.5 million in 2017, then jumped by 30.84% to $7.2 million in 2018, then climbed by 29.13% to $9.3 million in 2019.
• According to Business Quant data, Research & Development over the past three periods registered $9.3 million, $7.5 million, and $1.7 million for Q3 2019, Q2 2019, and Q1 2019 respectively.